MiroBio is a clinical-stage private biotechnology company focused on developing a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients
MiroBio is a clinical-stage private biotechnology company focused on developing a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients. The company has developed I-ReSToRE, a proprietary discovery platform that combines a receptor mapping database with antibody engineering.